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Considerable evidence indicates that eosinophils are important effectors of ocular allergy.
Increased worldwide prevalence of allergic eye pathologies has stimulated the identifica-
tion of novel drug targets, including eosinophils and adhesion molecules. Accumulation
of eosinophils in the eye is a key event in the onset and maintenance of allergic inflam-
mation and is mediated by different adhesion molecules. Antihistamines with multiple
mechanisms of action can be effective during the early and late phases of allergic conjunc-
tivitis by blocking the interaction between β1 integrins and vascular cell adhesion molecule
(VCAM)-1. Small molecule antagonists that target key elements in the process of eosinophil
recruitment have been identified and reinforce the validity of α4β1 integrin as a therapeu-
tic target. Glucocorticoids are among the most effective drugs for ocular allergy, but their
use is limited by adverse effects. Novel dissociated glucocorticoids can prevent eosinophil
accumulation and induce apoptosis of eosinophils, making them promising candidates for
ophthalmic drugs. This article reviews recent understanding of the role of adhesion mole-
cules in eosinophil recruitment in the inflamed conjunctiva along with effective treatments
for allergic conjunctivitis.
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INTRODUCTION
Ocular allergy is a disease primarily characterized by an inflamma-
tory response of the conjunctival mucosa (Origlieri and Bielory,
2009). Allergic conjunctivitis is the most common form of ocu-
lar allergy. The term “allergic conjunctivitis” refers to a collec-
tion of disorders that affect the lid, conjunctiva, and/or cornea.
Although allergic conjunctivitis is not generally life threatening,
the symptoms of ocular allergy may have a significant impact on
quality of life. Ocular symptoms are one of the most frequent
reasons for consultation among patients with allergic rhinocon-
junctivitis (Abelson et al., 2003). Acute forms of ocular allergy
involve transient symptoms of itching, tearing, and swelling,
while chronic allergies are sight-threatening and exhibit symp-
toms such as severe pain and visual disturbances (Leonardi,
1999).
Ophthalmic anti-allergic treatment includes topical mast
cell stabilizers, oral and topical antihistamines, antihistamine-
vasoconstrictor combinations, dual action agents with mast cell-
stabilizing, and antihistaminic properties, and anti-inflammatory
agents including steroids and non-steroidal drugs. Topical ocu-
lar corticoids are very effective, but display frequent side effects
such as glaucoma, cataracts, and corneal ulcers (Ono and Abelson,
2005).
In the following sections, we review eosinophil adhesion
molecules and the mechanisms involved in the recruitment of
eosinophils to the allergic conjunctiva. Cell adhesion-based ther-
apeutic strategies and the use of dissociated glucocorticoid in
allergic conjunctivitis are also conceptualized.
CONTRIBUTION OF EOSINOPHILS TO CONJUNCTIVAL
INFLAMMATION
The ocular allergic response results from exposure of the con-
junctiva to an environmental allergen with subsequent binding
of specific immunoglobulin E molecules onto conjunctival mast
cells. This immediate response lasts for 20–30 min and induces
enhanced tear levels of histamine, tryptase, prostaglandins, and
leukotrienes. Mast cell degranulation also induces activation of
vascular endothelial cells and expression of chemokines and adhe-
sion molecules (Ono and Abelson, 2005). These factors initiate
the recruitment phase of inflammatory cells into the conjunc-
tival mucosa, which leads to the late phase reaction. The late
phase corresponds to the persistent clinical inflammation observed
in perennial and chronic allergic diseases (Bacon et al., 2000),
and is characterized by the mucosal infiltration of eosinophils,
neutrophils, basophils, and T lymphocytes. In addition, conjunc-
tival and corneal epithelial cells and fibroblasts may contribute
to the allergic inflammatory response by inducing expression of
cytokines, chemokines, adhesion molecules, and factors that main-
tain local inflammation and lead to tissue remodeling (Kumagai
et al., 2006; Leonardi et al., 2006).
Eosinophils are multifunctional leukocytes implicated in the
pathogenesis of numerous inflammatory processes including par-
asitic helminth infections and allergic diseases (Rothenberg, 1998).
In response to diverse stimuli, eosinophils are recruited from
the circulation into inflammatory foci, where they modulate
immune responses through an array of mechanisms. Eosinophils
are produced from pluripotent stem cells in bone marrow, and
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their migration into the circulation is primarily regulated by
interleukin (IL)-5 (Collins et al., 1995). Circulating eosinophils
are subsequently extravasated by a regulated process involving the
coordinated interaction between chemokines, adhesion molecules
(α4β1, α4β7, αMβ2, αLβ2 integrins), and adhesion receptors on the
endothelium including mucosal addressin cell adhesion molecule
(MAdCAM)-1, vascular cell adhesion molecule (VCAM)-1, and
intercellular adhesion molecule (ICAM)-1.
Activation of eosinophils by cytokines, immunoglobulins, and
complement can lead to the secretion of an array of chemokines
and lipids (Kita, 1996), which have proinflammatory effects
including upregulation of adhesion systems, modulation of cel-
lular trafficking, and activation and regulation of vascular per-
meability, mucus secretion, and smooth muscle constriction.
Therefore, it is reasonable to consider eosinophils to be multi-
faceted leukocytes that contribute to various physiological and
pathological processes depending on their location and activation
status.
ROLE OF ADHESION MOLECULES IN THE MULTISTEP
PARADIGM OF EOSINOPHIL TRAFFICKING DURING
INFLAMMATION
Accumulating evidence indicates that the selective recruitment
of eosinophils is elegantly orchestrated by interactions between
chemokines and adhesion molecules (Ebnet et al., 1996). Such
translocations to tissue sites prime eosinophils to become even
more susceptible to subsequent stimuli (so-called outside-in
signaling; Bochner, 2000). This mechanism not only facili-
tates eosinophil functions within the tissue but may also pre-
vent systemic over-activation of circulating eosinophils. The
recruitment of eosinophils to inflamed tissue is a multistage
process in which eosinophils undergo (1) priming, (2) rolling
and tethering along endothelial cells, (3) firm adhesion to the
endothelium, (4) transendothelial diapedesis, and (5) chemotaxis
to the inflammatory site (Broide and Sriramarao, 2001; Figure 1).
Eosinophils express numerous adhesion molecules. Most atten-
tion has focused on the highly expressed integrins including α4β7,
the CD18 family of molecules (β2-integrins), and the very late
antigen (VLA)-4 molecules (β1 integrins; Bochner and Schleimer,
1994). The CD18 family of molecules includes lymphocyte func-
tion antigen (LFA)-1 and Mac-1, which interact with endothelial
cells via ICAM-1. VLA-4 interacts with endothelium via VCAM-1
or fibronectin (FN), while α4β7 integrin interacts with MAdCAM-
1 on vascular endothelium. These integrins have variable roles in
eosinophil trafficking during inflammation. It is now clear that
engagement of eosinophil adhesion molecules with their ligands
not only induces a pro-adhesive pathway, but also activates expres-
sion of proinflammatory genes that propagate eosinophil survival
by a paracrine pathway.
The first step of eosinophil recruitment involves tethering
to the endothelium mediated by P-selectin glycoprotein ligand-
1, l-selectin, and P-selectin, followed by α4 integrin-dependent
rolling along the vessel wall. Following activation by selective
chemokines (eotaxin and CCL5/RANTES), rolling eosinophils
engage α4 (α4β1 and α4β7) and β2 (αMβ2 and αLβ2) integrins
to firmly adhere to vascular endothelial cells. This process requires
firm adhesion of eosinophils mediated by α4β1 integrin-VCAM-1
interactions, increased affinity of β2 integrins for ICAM-1, and
then detachment of α4β1 integrin from VCAM-1 (Kuijpers et al.,
1993; Alblas et al., 2001). If detachment of α4β1 integrin from
VCAM-1 is inhibited,eosinophils will remain stuck to the endothe-
lium, and will not undergo transendothelial migration (Kuijpers
et al., 1993). In contrast to the predominant role for VCAM-1
in the recruitment of eosinophils, recruitment of lymphocytes
FIGURE 1 | Multistep process of eosinophil trafficking. Circulating
leukocytes initially tether and roll on endothelium via selectins and α4β1
integrin, followed by firm adhesion to endothelium via β1 and β2 integrins, and
subsequent extravasation between endothelial cells. Cell adhesion-based
therapeutic strategies specifically target adhesion molecules. For example,
bimosiamose, a selectin antagonist, blocks the recruitment of eosinophils
mediated by E-selectin. The antihistamine levocabastine, several small
antagonists, and the monoclonal antibody natalizumab can interfere with the
interaction between α4β1 integrin and VCAM-1, while efalizumab and
levocabastine can affect αLβ2/ICAM-mediated adhesion.
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is far less dependent on VCAM-1 (Barthel et al., 2006). Finally,
in the presence of chemotactic gradients, adherent eosinophils
migrate between endothelial cells to facilitate subsequent extrava-
sation or migration of eosinophils into tissues (Edwards et al.,
2000).
The identification of molecules that specifically regulate
eosinophil function and/or production offers a new therapeutic
strategy that may be useful for the treatment of allergic and inflam-
matory pathologies. Agents that interrupt eosinophil adhesion to
the endothelium by disrupting interactions between CD18 and
ICAM-1 or VLA-4 and VCAM-1 are currently being developed.
CELL ADHESION-BASED THERAPEUTIC STRATEGIES
Adhesion molecules and their intracellular signals are targets for
intervention to disrupt eosinophil recruitment. In recent years,
advancement in understanding of the pathophysiology of ocu-
lar allergies has paved the way for the development of newer
drug candidates. Inhibitors of selectins and integrins have been
used to block eosinophilia and inflammation in research stud-
ies and clinical trials. The small molecule pan-selectin antagonist
bimosiamose (TBC-1269) blocks E-selectin-mediated leukocyte
recruitment and attenuates late asthmatic reactions after allergen
challenge in mild asthmatics (Romano, 2005; Beeh et al., 2006;
Figure 1).
Several small molecule antagonists of α4β1 integrin have been
developed. Compound A, a non-peptidyl small molecule, blocks
eosinophil accumulation in the lungs of mice that have been chal-
lenged with ovalbumin (Koo et al., 2003). WAY103 blocks the
binding of human eosinophils to recombinant human VCAM-1
(Sedgwick et al., 2005). TR14035, an orally active dual antagonist
of the α4β1/α4β7 integrins, reduces eosinophil infiltration into the
rat lung by inhibiting leukocyte rolling and adhesion (Cortijo et al.,
2006). Valategrast (R411), a small molecule antagonist of α4β1
integrin, represents a potential therapy for asthma (Woodside and
Vanderslice, 2008).
Efalizumab (Raptiva) is a monoclonal antibody directed against
CD11a, the alpha subunit of LFA-1. Efalizumab inhibits LFA-1
(Li et al., 2009) by sterically hindering the interaction between
LFA-1 and ICAM-1 (Krueger, 2002; Jullien et al., 2004). Efal-
izumab also inhibits the extravasation and activation of T lym-
phocytes, as well as interactions between T lymphocytes and
keratinocytes (Jullien et al., 2004; Schön, 2008). Efalizumab was
approved for the treatment of moderate to severe plaque psori-
asis (Frampton and Plosker, 2009), but was withdrawn from the
market in 2009 because of three cases of progressive multifocal
leukoencephalopathy (Korman et al., 2009).
The validity of VLA-4 as a therapeutic target in humans
has been confirmed by natalizumab (Tysabri™), which was
the first adhesion molecule antagonist tested in a clinical trial
for patients with multiple sclerosis and other inflammatory
disorders (Miller et al., 2003). Natalizumab is a humanized
recombinant monoclonal antibody that binds to the alpha sub-
units of the α4β1 and α4β7 integrins. Natalizumab reduces
extravasation of leukocytes into peripheral tissues by inter-
fering with the physical interaction of α4β1 integrin with
its natural ligands, VCAM-1 and FN (Stüve and Bennett,
2007). Nevertheless, the use of natalizumab is complicated
by rare cases of progressive multifocal leukoencephalopathy
(Kleinschmidt-Demasters and Tyler, 2005; Langer-Gould et al.,
2005).
The adhesion-based therapeutic strategies targeting α4 integrin
seem promising for ocular allergy. In addition to its effects on H1
histamine receptors, levocabastine, but not the first-generation
antihistamine chlorpheniramine, binds to human integrin α4β1
and prevents eosinophil adhesion to VCAM-1, FN, and human
umbilical vascular endothelial cells in vitro. Similarly, levocabas-
tine affects αLβ2/ICAM-1-mediated adhesion of Jurkat cells. In a
model of allergic conjunctivitis, levocabastine eye drops reduced
the clinical aspects of the late phase reaction and the conjuncti-
val expression of α4β1 integrin by reducing eosinophil infiltration
(Qasem et al., 2008). These data confirm that levocabastine is an
antihistamine with multiple mechanisms of action that inhibit
the early and late phases of allergic reaction (Bielory et al., 2005).
Moreover, topical levocabastine reduces the expression of ICAM-
1 on epithelial conjunctival cells in vivo and in vitro (Buscaglia
et al., 1996; Bielory et al., 2005). Other anti-allergic agents, such as
azelastine (Ciprandi et al., 1996), cetirizine, olopatadine (Schultz,
2006), or fexofenadine (Ciprandi et al., 2003) may also reduce
ICAM-1 expression. In contrast, the antihistamine levocetirizine
inhibits adhesion of eosinophils to VCAM-1 (Wu et al., 2005).
In patients with allergic conjunctivitis, H1-antihistamines relieve
more relevant symptoms, such as itching, erythema, tearing, and
edema, and have a more favorable benefit-risk ratio than all
other classes of medications (Anonymous, 2010; Bohets et al.,
2011).
Use of antihistamines in allergic conjunctivitis has evolved,
and knowledge of the mechanisms of disease has progressed.
Histamine is more specifically antagonized by second generation
antihistamines, while newly formed mediators and downstream
effectors (prostaglandins, leukotrienes, ILs, adhesion molecule,
tumor necrosis factor, eosinophils, and neutrophils) are more
selectively antagonized by dual/multiple-action agents, such as
ketotifen, olopatadine, bepotastine, and alcaftadine, which have
been shown to have effects on the early and late phases of ocular
allergy. In fact, these drugs act as H1 receptor antagonists and
mast cell stabilizers. Moreover, both ketotifen and olopatadine
were able to decrease the expression of inflammatory markers
and adhesion molecules on conjunctival cells in patients with
allergic conjunctivitis (Avunduk et al., 2005). Some of the third
generation antihistamines inhibit the vacuolization and accumu-
lation of eosinophils after allergen challenge and directly inhibit
eosinophils in vitro (Rothenberg and Hogan, 2006). Bepotas-
tine, an antihistamine with mast cell-stabilizing activity, also has
been shown to inhibit the late phase reaction through multi-
ple mechanisms including histamine H1 receptor antagonism,
mast cell stabilization, and inhibition of eosinophil migration
to ocular inflammatory sites (Kida et al., 2010). Rupatadine is
a selective and long-acting new drug with a strong antagonis-
tic activity toward both histamine H1 receptors and platelet-
activating factor receptors. It showed potent anti-allergic activ-
ity in vitro, including inhibition of mast cell degranulation and
eosinophil chemotaxis, and in vivo (Sudhakara et al., 2009); more-
over, rupatadine can inhibit CD18 and CD11b (Barron et al.,
2004).
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GLUCOCORTICOIDS MODULATE EOSINOPHIL
ACCUMULATION IN ALLERGIC CONJUNCTIVITIS
Glucocorticoids are potent drugs and among the most effec-
tive for the treatment of allergic eye disease (Ono and Abelson,
2005). Their efficacy is due in part to the prevention of eosinophil
accumulation, activation, and induction of eosinophil apoptosis,
suppression of the synthesis and release of eosinophil survival fac-
tors, and stimulation of eosinophil engulfment by phagocytic cells
(Druilhe et al., 2003). Glucocorticoids like hydrocortisone, tri-
amcinolone, fluromethalone, rimexalone, prednisolone, and dex-
amethasone have been widely used in the treatment of allergic
conjunctivitis (Mishra et al., 2011).
Glucocorticoids reduce eosinophilia by suppressing transcrip-
tion of a number of genes for inflammatory mediators including
IL-3, IL-4, IL-5, granulocyte macrophage colony-stimulating fac-
tor, and various chemokines including the eotaxins. One of the
main actions of glucocorticoids on eosinophil-activating cytokines
is destabilization of mRNA, resulting in reduced half-life of
cytokines such as eotaxins (Stellato et al., 1999). In addition, gluco-
corticoids inhibit the cytokine-dependent survival of eosinophils
(Schleimer and Bochner, 1994).
Concerning glucocorticoid treatment of the eyes, the therapeu-
tic effects are powerful and rapid, but, unfortunately, their anti-
inflammatory and immunosuppressive effects frequently occur
with significant adverse effects that may limit their use (Frauman,
1996). At the ocular level, classical glucocorticoids may cause eleva-
tion of intraocular pressure, which may lead to glaucoma (Kersey
and Broadway,2006) and cataract formation (Carnahan and Gold-
stein, 2000). There is, therefore, a pressing need for compounds
with the anti-inflammatory potency of standard glucocorticoids
but fewer undesired side effects.
Glucocorticoids exert their actions as a consequence of pene-
trating the cytoplasm and binding to the glucocorticoid receptor.
The glucocorticoid–glucocorticoid receptor complex reaches the
nucleus and acts as a transcription factor by binding to spe-
cific DNA sites and modifying transcription. This can have two
effects on gene transcription. It can either activate transcription
(transactivation) by directly binding to the promoter region of
target genes or by interacting with other transcription factors,
such as activator protein-1, nuclear factor-kappa B, and others, or
it can suppress transcription (transrepression; Biddie and Hager,
2009).
It has been hypothesized that transrepression is the key
mechanism of the anti-inflammatory effects of glucocorticoids,
whereas transactivation has been assumed to cause side effects.
In fact, transactivation activity has been implicated in many
of the adverse effects associated with glucocorticoid therapy
(Schäcke and Rehwinkel, 2004); the glucocorticoid-induced ele-
vation of intraocular pressure seems to be primarily related to
transactivation. Although glucocorticoids enhance the transac-
tivation and expression of anti-inflammatory genes including
lipocortin-1 and inhibitor of nuclear factor-kappa B, the tran-
srepression mechanism may not be sufficient to explain their
anti-inflammatory effects (Reichardt et al., 2001). However, in
an admittedly oversimplified model, the dissociation of tran-
srepression and transactivation has long been considered to be
pivotal to the separation of the therapeutic and side effects of
glucocorticoid therapy. Many researchers are trying to develop
new drugs, dissociated compounds, or selective glucocorticoid
receptor agonists (SEGRAs) that should preserve the beneficial
anti-inflammatory activity but offer a better side effect profile.
The identification of SEGRAs with separable transrepression and
transactivation activities represents an important research goal in
steroid pharmacology.
Mapracorat (also known as ZK245186 or BOL-303242-X) is
a novel selective glucocorticoid receptor agonist that maintains a
beneficial anti-inflammatory activity but seems to be less effective
in transactivation, resulting in a lower potential for side effects.
Mapracorat has been proposed for topical treatment of inflam-
matory skin and ocular disorders. In cultured human eosinophils,
mapracorat shows the same potency as dexamethasone but dis-
plays higher efficacy in increasing spontaneous apoptosis and
counteracting cytokine-sustained eosinophil survival (Baiula et al.,
2011). In an in vivo model of allergic conjunctivitis, mapracorat, or
dexamethasone eye drops induce an analogous reduction in clin-
ical symptoms and conjunctival eosinophil accumulation (Baiula
et al., 2011).
Recently, it was reported that mapracorat acts as a partial gluco-
corticoid receptor agonist at therapeutic doses and elicits a lower
myocilin expression profile in monkey trabecular meshwork cells
in comparison with traditional ocular steroids (Cavet et al., 2010).
Mapracorat that is topically administered as eye drops displays a
reduced ability to increase intraocular pressure in normotensive
rabbits when compared to dexamethasone (Shafiee et al., 2011).
Mapracorat appears to be a promising candidate for topical
treatment of allergic eye disorders and is under investigation in
several clinical trials. Mapracorat maintains an anti-allergic profile
similar to that of dexamethasone, but seems to have fewer trans-
activation effects in comparison to that classical glucocorticoid.
The inhibitory effect of mapracorat on eosinophil accumulation
observed in vivo at the conjunctival level may involve various
mechanisms including eosinophil apoptosis and recruitment and
activation or release of cytokines and chemokines. The contribu-
tion of glucocorticoids to eosinophil apoptosis in allergic diseases
in vivo remains to be investigated further.
Several pharmaceutical companies have been trying to dis-
cover SEGRAs with therapeutically beneficial profiles (Berlin,
2010). Intensive research efforts led to the discovery of promis-
ing compounds that are at the preclinical developmental stage or
early clinical stage. It is uncertain whether a complete separation
of transactivation and transrepression will result in compounds
with decreased adverse effect profiles. Although transactivation
is thought to be responsible for the deleterious side effects of
chronic glucocorticoid treatment, some transactivation events
have shown therapeutic benefit. Indeed, the anti-inflammatory
process is mediated by transactivating, transrepressing, and non-
genomic actions of the glucocorticoid receptor (Rhen and Cid-
lowski, 2005), suggesting that the search for truly dissociated
drugs in the treatment of inflammation may not be necessary.
Rather, it may be necessary to search for “differential” glucocor-
ticoid receptor agonists that show the most favorable functional
profiles.
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CONCLUSION
Several drug targets in allergic conjunctivitis have been identified
in the past several years. These advancements have opened the
way for the development of newer drug candidates and for a bet-
ter understanding of the mechanisms of action of currently used
drugs.
Based on available research, dual action antihistamines are
efficacious for the treatment of allergic conjunctivitis. Multiple
mechanisms of action exist for antihistamines such as levocabas-
tine. Targeting adhesion molecules appears to be particularly
interesting. This contributes to improved effects on early (medi-
ated by antihistamine action) and late (mediated by blocking
integrin-mediated cell adhesion) phases of ocular allergy.
Glucocorticoids are among the most effective anti-
inflammatory drugs employed for allergic eye diseases, although
the risk of adverse effects may limit their use. Glucocorticoids that
dissociate transrepression and transactivation are actively being
pursued in order to better separate therapeutic and side effects.
Mapracorat, a promising dissociated SEGRA candidate for the
treatment of allergic conjunctivitis, can prevent eosinophil accu-
mulation and activation and induce eosinophil apoptosis in vitro.
These effects have been confirmed in vivo using a model of allergic
conjunctivitis. In fact, mapracorat was able to increase apoptosis
of eosinophils in the conjunctival tissue of ovalbumin-sensitized
guinea pigs (Baiula et al., unpublished results).
Improved comprehension of the molecular mechanisms of
action of drugs used in ocular allergy will be valuable for increas-
ing the efficacy and safety of drugs and for the discovery of novel
therapies.
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